|
|
|
|
|
|
|
|
|
30.04.26 - 22:06
|
How Ketamine Spawned a $1.7 Billion J&J Blockbuster Drug (Bloomberg)
|
|
|
Spravato, the ketamine-derived nasal spray from Johnson & Johnson, was once seen as a long shot. It was difficult to deliver, heavily regulated and slow to catch on. Find out how it became a billion-dollar drug and part of a new model for treating depression.
(Source: Bloomberg)...
|
|
|
30.04.26 - 14:03
|
Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations (Business Wire)
|
|
|
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) (the “Company”) today announced the appointment of Ryan Koors to Vice President, Investor Relations, effective May 7, 2026. Mr. Koors will report to Johnson & Johnson's Executive Vice President and Chief Financial Officer, Joseph J. Wolk. He succeeds Darren Snellgrove who is leaving the company to become the chief financial officer of Halozyme.
“Ryan's appointment underscores the deep bench of financial talent within Johnson & Johnson and our commitment to developing leaders across the Company,” said Mr. Wolk. “With his deep knowledge of our business and proven financial expertise, Ryan is exceptionally well positioned to lead our Investor Relations function and will be a great resource to the investment community as we continue to execute our long-term strategy, drive sustained and accelerating growth and create value for shareholders.”
Mr. Koors is an accomplished Johnson & Johnson finance leader with more than 20 years of...
|
|
|
29.04.26 - 17:42
|
3 Dividend Kings That Have Outrun the Nasdaq Over 12 Months (24/7 Wall St.)
|
|
|
The Nasdaq Index carries companies that are known for moving fast and breaking things. This is not always the case, and Dividend King stocks like Johnson & Johnson (NYSE:JNJ), Parker-Hannifin (NYSE:PH), and Gorman-Rupp (NYSE:GRC) outperforming the index in the past year prove it. Of course, you cannot expect Dividend Kings to outrun the Nasdaq forever if the AI ... 3 Dividend Kings That Have Outrun the Nasdaq Over 12 Months...
|
|
|
|
|
|
|
|
|
|
|
27.04.26 - 13:06
|
Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors (Business Wire)
|
|
|
Dr. Mates grew Intra-Cellular from discovery and early innovation through commercialization of CAPLYTA® and a $14.6 billion acquisition by Johnson & JohnsonBOSTON--(BUSINESS WIRE)--Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage therapeutics company that is inventing and developing neuropsychiatric medicines, today announced the appointment of Dr. Sharon Mates to its Board of Directors.
Dr. Mates served as the Co-Founder, Chairman, and Chief Executive Officer of Intra-Cellular Therapies, Inc. from inception of the company in June 2002 until its acquisition by Johnson & Johnson (J&J) in 2025 for approximately $14.6 billion. She has decades of experience in neuropsychiatry, guiding a company she founded through successful commercialization and a major strategic transaction.
“Sharon is an exceptional biotech entrepreneur and leader whom I have admired for years. We are delighted to welcome her to our Board,” said Daphne Zohar, Founder and Chief Executive Officer of Seaport Th...
|
|
|
27.04.26 - 13:06
|
PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors (Business Wire)
|
|
|
BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes that its Founded Entity, Seaport Therapeutics, today announced the appointment of Dr. Sharon Mates to its Board of Directors.
Dr. Mates served as the Co-Founder, Chairman, and Chief Executive Officer of Intra-Cellular Therapies, Inc. from inception of the company in June 2002 until its acquisition by Johnson & Johnson (J&J) in 2025 for approximately $14.6 billion. She has decades of experience in neuropsychiatry, guiding a company she founded through successful commercialization and a major strategic transaction.
The full text of the announcement from Seaport is as follows:
Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors
Dr. Mates grew Intra-Cellular from discovery and early innovation through commercia...
|
|
|
|
|
|
|
|
|
24.04.26 - 13:06
|
A $900,000 Stock Portfolio Exposed to Just Three Sectors Is a Retirement Time Bomb (24/7 Wall St.)
|
|
|
At 63, with $900,000 in a brokerage account split across tech (45%), healthcare (30%), and financials (25%), you have built something real. The five holdings — Apple (NASDAQ:AAPL), Microsoft (NASDAQ:MSFT), Johnson & Johnson (NYSE:JNJ), UnitedHealth Group (NYSE:UNH), and JPMorgan Chase (NYSE:JPM) — are legitimate blue-chip businesses. The problem is what happens to all three sectors ... A $900,000 Stock Portfolio Exposed to Just Three Sectors Is a Retirement Time Bomb...
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
